Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study

Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study

2016 Epilepsy Res

Brodie, M. J. | Chung, S. | Wade, A. | Quelen, C. | Guiraud-Diawara, A. | Francois, C. | Verpillat, P. | Shen, V. | Isojarvi, J. | Volume: 123, Issue: , Pages: 68-74, Adolescent, Adult, Age Factors, Anticonvulsants/*therapeutic use, Benzodiazepines/*therapeutic use, Child, Child, Preschool, Clonazepam/*therapeutic use, Cohort Studies, Epilepsy/*drug therapy, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Outcome Assessment (Health Care), Time Factors, United Kingdom, All epilepsy/seizures, Antiepileptic drugs, Clobazam, Clonazepam, Outcome research,

OBJECTIVE: To compare patient characteristics and treatment patterns among clobazam (CLB) and clonazepam (CZP)-treated patients with epilepsy in a longitudinal primary care database. METHODS: In this pharmacoepidemiological study, real-life usage data from the Clinical Practice Research Database (CPRD) were evaluated. The CPRD collects data from approximately 690 primary care practices throughout the UK. Data included were from patients with >/=1 incident CLB or CZP prescription from 1995 to 2011 and were present in the database for >/=182 days prior to the index date (date patient was first prescribed CLB or CZP within the study period). RESULTS: Of 21,099 patients who met inclusion criteria, 18.4% were receiving CLB and 81.6% were receiving CZP. More patients used CLB for epilepsy than CZP (76.1% vs 8.7%). CLB-treated adults (

https://www.doi.org/10.1016/j.eplepsyres.2016.04.003